or Try an Advanced Search...

    Technical Analysis for APGE - Apogee Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 45.04 -3.18% -1.48
    APGE closed down 3.18 percent on Wednesday, November 20, 2024, on 84 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical APGE trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -3.18%
    NR7-2 Range Contraction -3.18%
    Lower Bollinger Band Walk Weakness -3.18%
    Wide Bands Range Expansion -3.18%
    Lower Bollinger Band Touch Weakness -3.18%
    Oversold Stochastic Weakness -3.18%
    Older End-of-Day Signals for APGE ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Lower Bollinger Band about 16 hours ago
    Outside Day about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Down 3% about 17 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    APGE Chart by TradingView
    Basic chart:

    Profile

    Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd

    Is APGE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
    Nov 14 Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
    Nov 13 Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
    Nov 12 Apogee Therapeutics reports Q3 results
    Nov 12 Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
    Nov 10 Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
    Nov 4 Apogee Therapeutics to Participate in Upcoming November Investor Conferences
    Oct 24 Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
    Oct 16 Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
    Oct 7 Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now
    See more APGE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 72.29
    52 Week Low 16.39
    Average Volume 413,331
    200-Day Moving Average 49.89
    50-Day Moving Average 54.57
    20-Day Moving Average 53.81
    10-Day Moving Average 52.49
    Average True Range 3.41
    RSI (14) 33.33
    ADX 21.78
    +DI 14.38
    -DI 30.38
    Chandelier Exit (Long, 3 ATRs) 53.27
    Chandelier Exit (Short, 3 ATRs) 54.60
    Upper Bollinger Bands 63.29
    Lower Bollinger Band 44.33
    Percent B (%b) 0.04
    BandWidth 35.24
    MACD Line -1.94
    MACD Signal Line -0.48
    MACD Histogram -1.4619
    Fundamentals Value
    Market Cap 2.16 Billion
    Num Shares 48 Million
    EPS
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 48.54
    Resistance 3 (R3) 48.70 47.70 47.95
    Resistance 2 (R2) 47.70 46.81 47.62 47.76
    Resistance 1 (R1) 46.37 46.26 45.87 46.21 47.56
    Pivot Point 45.37 45.37 45.12 45.29 45.37
    Support 1 (S1) 44.04 44.48 43.54 43.88 42.52
    Support 2 (S2) 43.04 43.93 42.96 42.32
    Support 3 (S3) 41.71 43.04 42.13
    Support 4 (S4) 41.55